OSCEOLA, Wis. and MOUNTAIN VIEW, Calif., July 23, 2014 /PRNewswire-iReach/ -- Surpass, Inc. ("Surpass"), a recognized leader in translational preclinical research, today unveiled their new logo and corporate website (found at www.surpassinc.com), signaling the transformation of Surpass' corporate culture to one where our team is an integrated innovation partner for our customers. This press release comes on the heels of the announcement last week that two integral hires were added to the Silicon Valley Team: David Craig, a veteran preclinical scientist and expert veterinary interventionalist, and Benigno Mills, a veterinary surgical and interventional specialist.
"The launch of our new logo and website signifies the beginning of a new era for Surpass. We have refined our company's culture in response to the ever-changing needs of our customers. What customers needed 5 or 10 years ago is very different from today. With increasing pressures on the healthcare dollar, every stakeholder in the medical innovation continuum needs to work in concert. Long gone are the days where engineering, preclinical research, regulatory, and other entities operate separately. To stay competitive, the life science industry as a whole needs to be connected in ways that enable us to develop new medical solutions faster, better, and cheaper. This only happens in a true team environment where the task is supreme," said Dr. Tim Pelura, President and CEO of Surpass. "We at Surpass bring much more to our client partners. We provide insightful solutions and support every step of the way as a valuable extension of your product development team. Our People are Your Team. Surpass customizes our services to meet your specific project need. We're changing the rules for a better way to get from concept to reality."
"The new logo signifies Surpass' commitment to be an integrated preclinical partner for our customers - two vibrantly colored hemispheres coming together as one team," commented Denise Forkey, Senior Director of Marketing and Corporate Communications for Surpass. "The hemispheres are joined by an artistic rendition of the EKG wave signifying the importance and vitality of the work we perform within the global life science community every day at Surpass."
To hear Dr. Pelura talk about how Surpass partners with our clients to advance life-saving products into the hands of physicians and patients, visit our website.
Our innovative approach to preclinical research goes beyond the ordinary. We're changing the rules for a better way to get from concept to reality.
Surpass is a trusted contract research organization (CRO) with extensive experience conducting medical device, pharmaceutical, biotech and combination product studies with specialized expertise in surgical and interventional procedures. Our testing services include early feasibility, product development, GLP, and physician/clinical training studies. At Surpass, we provide insightful solutions and support every step of the way, offering expert advice and the level of comprehensive support needed to make your study successful – the first time.
Surpass' breadth of case experience in preclinical studies includes feasibility and safety assessments of ablation systems, vascular grafts, orthopedic prostheses, stents, closure devices, valves, infusion pumps, drug coated balloons, neurostimulators, pharmaceuticals, biologics, imaging systems, cardiac assist devices, and more. Whether you are a startup or an established player, Surpass is uniquely qualified to make your study successful. Contact Surpass today at (651) 433-4277 (Greater Twin Cities) or (650) 477-8267 (Silicon Valley).
Media Contact: Denise Forkey, Surpass, Inc., 650-938-2101, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
|SOURCE Surpass, Inc.|
Copyright©2014 PR Newswire.
All rights reserved